MedTrace Logo

Sonazoid Enhanced Liver Cancer Trial for Early Detection

NCT00822991 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 760

Last updated 2010-12-30

No results posted yet for this study

Summary

The aim of this study is to prove usefulness of contrast-enhanced ultrasound (CE-US) using Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound (B-mode US) for hepatitis virus related cirrhosis, who are defined as super high-risk patients for hepatocarcinogenesis,Furthermore, to analyze whether early detection of HCC by CE-US has a survival benefit than that by B-mode US.

Conditions

Interventions

DEVICE

CE-US (Sonazoid™)

screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months

DEVICE

B-mode US

screening by conventional B-mode US every 3-5 months

Sponsors & Collaborators

  • Kindai University

    lead OTHER

Principal Investigators

  • Masatoshi Kudo, professor · Kindai University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00822991 on ClinicalTrials.gov